United States Patent 11,185,538: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 11,185,538, titled "Compositions for treating glaucoma or reducing intraocular pressure," is a significant patent in the field of ophthalmology, particularly in the treatment of glaucoma and reduction of intraocular pressure. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.
Patent Overview
Publication Details
The patent, numbered US11185538B2, was published on October 12, 2021, and is assigned to Aerie Pharmaceuticals, Inc.[4].
Invention Summary
The patent describes compounds and compositions for treating glaucoma and/or reducing intraocular pressure. These compositions may include isoquinoline derivatives, which are known for their therapeutic effects in ophthalmic treatments.
Claims Analysis
Independent Claims
The patent includes several independent claims that define the scope of the invention. These claims typically outline the specific compounds, compositions, and methods of use that are protected under the patent.
- Claim 1: This claim often sets the broadest scope of the invention, defining the general class of compounds or compositions covered by the patent.
- Claim 2-10: These claims typically narrow down the scope by specifying particular aspects of the compounds or compositions, such as specific chemical structures, formulations, or methods of administration.
Dependent Claims
Dependent claims build upon the independent claims, providing additional details and limitations that further define the invention. These claims help to ensure that the patent covers a range of variations and applications of the invention.
Patent Scope
Therapeutic Applications
The patent is focused on therapeutic applications for treating glaucoma and reducing intraocular pressure. The compositions described are designed to be effective in managing these conditions, which are significant health issues affecting millions worldwide.
Chemical Compounds
The patent specifies isoquinoline derivatives as key components of the compositions. These compounds are highlighted for their efficacy in treating glaucoma and reducing intraocular pressure.
Patent Landscape
Related Patents
The patent landscape around US11185538B2 includes several related patents, particularly those owned by Aerie Pharmaceuticals, Inc. For example:
- US Patent 10,588,901: This patent is also related to compositions and methods for treating eye diseases, including glaucoma and ocular hypertension[2].
- US Patent 11,028,081: This patent is a continuation of another patent and deals with dual mechanism inhibitors for the treatment of diseases, including glaucoma[5].
Litigation and Enforcement
The patent has been involved in litigation, as seen in the case where Aerie Pharmaceuticals, Inc. alleged infringement by Gland Pharmaceuticals. The lawsuit highlights the importance of this patent in protecting Aerie's intellectual property and the commercial value of the compositions described[2][5].
Global Dossier and International Implications
The Global Dossier service provided by the USPTO allows users to access the file histories of related applications from participating IP Offices, including the IP5 Offices. This service can be useful in understanding the international patent family and any office actions related to this patent[1].
Public Search and Resource Centers
For those interested in further research, the USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs) offer valuable resources. These facilities provide access to patent and trademark information, including the ability to search and review patent documents such as the one in question[1].
Common Citation Document (CCD)
The Common Citation Document (CCD) application consolidates prior art cited by all participating offices for the family members of a patent application. This tool can help in understanding the prior art landscape and how this patent fits into it[1].
Economic and Research Implications
The Patent Claims Research Dataset provided by the USPTO can offer insights into the scope and trends of patent claims, including those related to this patent. This dataset can be useful for researchers and economists studying the impact of patents on innovation and market competition[3].
Key Takeaways
- Patent Scope: The patent covers compositions for treating glaucoma and reducing intraocular pressure, specifically focusing on isoquinoline derivatives.
- Claims: The patent includes independent and dependent claims that define the specific compounds, compositions, and methods of use.
- Patent Landscape: The patent is part of a broader landscape that includes related patents and ongoing litigation to protect intellectual property.
- Global Implications: The patent's international implications can be understood through services like the Global Dossier and CCD.
- Research and Economic Impact: The patent's impact can be analyzed using datasets like the Patent Claims Research Dataset.
Frequently Asked Questions (FAQs)
What is the main focus of United States Patent 11,185,538?
The main focus of this patent is on compositions for treating glaucoma and reducing intraocular pressure, specifically using isoquinoline derivatives.
Who owns United States Patent 11,185,538?
The patent is owned by Aerie Pharmaceuticals, Inc.
What are the key claims of this patent?
The key claims include independent claims defining the general class of compounds or compositions and dependent claims that narrow down the scope with specific details.
Is this patent involved in any litigation?
Yes, this patent has been involved in litigation, particularly in cases where Aerie Pharmaceuticals, Inc. has alleged infringement by other companies.
How can one access more information about this patent?
One can access more information through the USPTO Public Search Facility, Patent and Trademark Resource Centers (PTRCs), and services like the Global Dossier and Common Citation Document (CCD).
Cited Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- RPX Insight - Litigation Documents: https://insight.rpxcorp.com/litigation_documents/14657769
- USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
- Google Patents - US11185538B2: https://patents.google.com/patent/US11185538B2/en
- RPX Insight - Litigation Documents: https://insight.rpxcorp.com/litigation_documents/14657768
